NLRP3 and osteosarcoma: Upregulating HTR2B through lentiviral‐mediated gene delivery or the agonist BW‐723C86, resulted in a marked suppression of osteosarcoma cell progression via the STAT1‐NLRP3 inflammasome pathway.